Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Biogen paid Ionis a US $ 60 million one-time upfront payment
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Partnering to build biosynthesis processes and a pharmaceutical production platform
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Subscribe To Our Newsletter & Stay Updated
